Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu. Issue 5 (3rd May 2016)

• Record Type: Journal Article
• Authors: Klimek, Ludger; Demoly, Pascal; Price, David
• Is Part Of: Expert review of clinical pharmacology. Volume 9:Issue 5(2016)
• Page Start: 705
• Page End: 714
• Publication Date: 2016-05-03
• Subjects: Allergic rhinitis -- effectiveness -- MP-AzeFlu -- real-life; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1586/17512433.2016.1148598
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also of effectiveness in real-life. Observational studies provide valuable data on the use and results associated with interventions prescribed in real-life. However, real-life evidence supporting available AR treatment options is sparse with effectiveness only established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immunotherapy and omalizumab. A novel intranasal formulation of azelastine hydrochloride and FP in a single spray (MP-AzeFlu) shows great promise, with the effectiveness observed in real-life exceeding that noted in RCTs. This review summarises real-life data on MP-AzeFlu, which provides rapid and sustained symptom control irrespective of patient age, AR phenotype or disease severity. We call for high quality real-life research in addition to RCTs to inform future AR treatment guidelines.